Longevity & Aging · Metabolic & Cardiometabolic
ApoB apolipoprotein B or LDL particle number predicts ASCVD risk better than LDL-C alone especially when discordant
In plain terms: Is ApoB a better heart-attack risk predictor than standard LDL cholesterol?
Yes — ApoB captures atherogenic particle number and outperforms LDL-C when the two disagree, though absolute gain over non-HDL-C is modest and it does not overturn LDL-C's causal role.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (10)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Li 2023 · J Geriatr Cardiol | observational | mixed | moderate | In statin-treated CAD patients, apoB and non-HDL-C showed broadly similar discrimination for recurrent myocardial infarction. |
| Wang 2026 · Eur J Prev Cardiol | observational | supports | moderate | ApoB-defined particle burden added risk stratification beyond LDL-C across the LDL-C distribution, supporting a particle-number axis over cholesterol mass alone. |
| Zubiran 2025 · Arterioscler Thromb Vasc Biol | observational | mixed | high | UK Biobank analysis found estimated small-dense LDL-C added risk information, indicating apoB is not uniquely superior among particle-based markers. |
| Marston 2022 · JAMA Cardiol | observational | supports | high | In FOURIER and IMPROVE-IT, apoB particle number predicted myocardial infarction better than LDL-C or triglyceride content. |
| Rehman 2026 · Eur Heart J | observational | mixed | moderate | Even apoB underestimates risk when remnants/Lp(a) are high, requiring a risk-weighted apoB metric — apoB is better than LDL-C but not a complete single marker. |
| Genedy 2026 · J Clin Lipidol | observational | supports | low | Hypothesis-generating HeFH cohort: apoB/LDL-C discordance flagged higher ASCVD risk despite apparently controlled LDL-C, but sparse and preliminary. |
| Hu 2025 · Transl Stroke Res | observational | supports | moderate | ApoB predicted recurrent ischemic stroke with greater discriminatory ability (AUC 0.732) than LDL-C (0.685). |
| Thanassoulis 2014 · J Am Heart Assoc | meta-analysis | supports | high | In statin RCTs, on-treatment apoB reduction related more closely to event reduction than LDL-C or non-HDL-C, favoring apoB as the treatment-adequacy marker. |
| Sniderman 2011 · Circ Cardiovasc Qual Outcomes | meta-analysis | supports | high | Head-to-head meta-analysis of LDL-C, non-HDL-C and apoB found apoB the single most potent marker of cardiovascular risk among the three. |
| Sniderman 2014 · Curr Opin Lipidol | observational | supports | moderate | Discordance analysis argues apoB outperforms LDL-C and non-HDL-C for cardiovascular risk when the measures disagree. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.